(Q54420490)

English

Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24352344

Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24352344

0 references

object named as

Virginie Bres

4

0 references

Jean-Louis Montastruc

8

object named as

Jean-Louis Montastruc

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

author name string

Jean-Luc Faillie

1

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24352344

Samy Babai

2

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24352344

Sabrina Crépin

3

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24352344

Marie-Laure Laroche

5

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24352344

Hervé Le Louet

6

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24352344

Pierre Petit

7

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24352344

Dominique Hillaire-Buys

9

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24352344

French Pharmacovigilance Centers Network

10

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24352344

publication date

19 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24352344

Acta Diabetologica

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24352344

51

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24352344

3

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24352344

491-497

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24352344

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Data mining in pharmacovigilance: the need for a balanced perspective

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

The role of data mining in pharmacovigilance

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Application of data mining techniques in pharmacovigilance

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Quantitative signal detection using spontaneous ADR reporting

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Drug-induced pancreatitis : incidence, management and prevention

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Under-reporting of adverse drug reactions : a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Incretin therapy and islet pathology: a time for caution

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

A cohort study of acute pancreatitis in relation to exenatide use.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Identifiers

10.1007/S00592-013-0544-0

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24352344

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/24352344

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54420490&oldid=2212460873"